![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LEAP2 |
Gene summary for LEAP2 |
![]() |
Gene information | Species | Human | Gene symbol | LEAP2 | Gene ID | 116842 |
Gene name | liver enriched antimicrobial peptide 2 | |
Gene Alias | LEAP-2 | |
Cytomap | 5q31.1 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q969E1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
116842 | LEAP2 | NAFLD1 | Human | Liver | NAFLD | 1.66e-05 | 6.56e-01 | -0.04 |
116842 | LEAP2 | S43 | Human | Liver | Cirrhotic | 3.46e-03 | 3.18e-02 | -0.0187 |
116842 | LEAP2 | HCC1_Meng | Human | Liver | HCC | 6.74e-75 | 2.95e-01 | 0.0246 |
116842 | LEAP2 | HCC2_Meng | Human | Liver | HCC | 4.23e-04 | -2.89e-01 | 0.0107 |
116842 | LEAP2 | cirrhotic1 | Human | Liver | Cirrhotic | 1.40e-03 | 1.67e-01 | 0.0202 |
116842 | LEAP2 | cirrhotic2 | Human | Liver | Cirrhotic | 1.79e-06 | 7.95e-02 | 0.0201 |
116842 | LEAP2 | cirrhotic3 | Human | Liver | Cirrhotic | 3.78e-02 | -2.91e-02 | 0.0215 |
116842 | LEAP2 | HCC1 | Human | Liver | HCC | 3.34e-10 | 3.93e+00 | 0.5336 |
116842 | LEAP2 | Pt13.a | Human | Liver | HCC | 2.73e-12 | 4.24e-01 | 0.021 |
116842 | LEAP2 | Pt13.b | Human | Liver | HCC | 2.34e-25 | 4.29e-01 | 0.0251 |
116842 | LEAP2 | Pt14.b | Human | Liver | HCC | 1.11e-03 | 2.64e-01 | 0.018 |
116842 | LEAP2 | S029 | Human | Liver | HCC | 2.40e-09 | 1.78e+00 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LEAP2 | SNV | Missense_Mutation | novel | c.164N>T | p.Arg55Leu | p.R55L | Q969E1 | protein_coding | deleterious(0) | benign(0.021) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
LEAP2 | insertion | In_Frame_Ins | novel | c.93_94insTTTGCCTCTTTGTCC | p.Ala31_Lys32insPheAlaSerLeuSer | p.A31_K32insFASLS | Q969E1 | protein_coding | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
LEAP2 | insertion | Frame_Shift_Ins | novel | c.94_95insGATTTATTCCC | p.Lys32ArgfsTer11 | p.K32Rfs*11 | Q969E1 | protein_coding | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
LEAP2 | SNV | Missense_Mutation | novel | c.175G>C | p.Glu59Gln | p.E59Q | Q969E1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A2H4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
LEAP2 | SNV | Missense_Mutation | rs771383357 | c.89N>T | p.Ser30Leu | p.S30L | Q969E1 | protein_coding | tolerated(0.17) | benign(0.011) | TCGA-BG-A0VZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
LEAP2 | SNV | Missense_Mutation | rs771383357 | c.89N>T | p.Ser30Leu | p.S30L | Q969E1 | protein_coding | tolerated(0.17) | benign(0.011) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LEAP2 | insertion | In_Frame_Ins | novel | c.96_97insTTTATATTTGTAATC | p.Lys32_Arg33insPheIlePheValIle | p.K32_R33insFIFVI | Q969E1 | protein_coding | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
LEAP2 | insertion | Frame_Shift_Ins | novel | c.102dupG | p.Pro35AlafsTer23 | p.P35Afs*23 | Q969E1 | protein_coding | TCGA-BC-A10W-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Chemotherapy | unknown | PD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |